Betaferon?? in early relapsing-remitting multiple sclerosis surveillance trial (BEST): A combined analysis of patients from Asia completing 2 years of treatment

BEST Study Group of Japan; BEST Study Group of Korea; C Meier; CP Tsai; J Kira; KW Lee; L Kappos; T Umapathi

首页> 外文期刊>Neurological Journal of South East Asia >Betaferon?? in early relapsing-remitting multiple sclerosis surveillance trial (BEST): A combined analysis of patients from Asia completing 2 years of treatment

【24h】

Betaferon?? in early relapsing-remitting multiple sclerosis surveillance trial (BEST): A combined analysis of patients from Asia completing 2 years of treatment

机译：Betaferon ??在早期复发-缓解型多发性硬化症监测试验（BEST）中：对亚洲患者完成2年治疗的综合分析

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Neurological Journal of South East Asia》 |2008年第2008期|共页
作者
BEST Study Group of Japan; BEST Study Group of Korea; C Meier; CP Tsai; J Kira; KW Lee; L Kappos; T Umapathi;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类神经科学;
关键词
入库时间 2022-08-18 12:05:09

相似文献

外文文献
中文文献
专利

1. Betaferon? in early relapsing-remitting multiple sclerosis surveillance trial (BEST): A combined analysis of patients from Asia completing 2 years of treatment [J] . BEST Study Group of Japan, BEST Study Group of Korea, C Meier, Neurology Asia . 2008,第2008期

机译：Betaferon？在早期复发-缓解型多发性硬化症监测试验（BEST）中：对亚洲患者完成2年治疗的综合分析
2. Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis [J] . Terranova Nadia, Hicking Christine, Dangond Fernando, Clinical pharmacokinetics . 2019,第3期

机译：克拉迪斯施用第二年延期治疗的影响：复发式多发性硬化症患者绝对淋巴细胞计数和复发率的临床试验仿真分析
3. Durable Effect of Alemtuzumab on Clinical Outcomes Over 5 years in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Despite Most Patients Not Receiving Treatment for 4 Years: CARE-MS I Extension Study [J] . McCombe P. A., Hartung H-P, Havrdova E., Multiple sclerosis: clinical and laboratory research . 2016,第3期

机译：尽管大多数患者未接受治疗，但初治患者主动复发缓解型多发性硬化症患者中Alemtuzumab对5年以上临床结局的持久影响：CARE-MS I扩展研究
4. GPU Accelerated Analysis of Treg-Teff Cross Regulation in Relapsing-Remitting Multiple Sclerosis [C] . Marco Beccuti, Paolo Cazzaniga, Marzio Pennisi, International Conference on Parallel and Distributed Computing . 2019

机译：GPU在复发延迟多发性硬化中的Treg-Teff交叉调节的分析
5. An investigation of early relapsing-remitting multiple sclerosis patients using diffusion tensor imaging and spectroscopy. [D] . Zaini, Wan Hazlin. 2013

机译：使用扩散张量成像和光谱法对早期复发缓解型多发性硬化症患者进行调查。
6. Risk Factors for Poor Adherence to Betaferon® Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome [O] . Łukasz Jernas, Jacek Wencel, Andrzej Wiak, -1

机译：复发缓解型多发性硬化症或临床孤立综合征患者依从性不佳的Betaferon®治疗危险因素
7. Risk Factors for Poor Adherence to Betaferon® Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome. [O] . Łukasz Jernas, Jacek Wencel, Andrzej Wiak, 2016

机译：复发缓解型多发性硬化症或临床孤立综合征患者对β干扰素治疗不良的危险因素。

Betaferon?? in early relapsing-remitting multiple sclerosis surveillance trial (BEST): A combined analysis of patients from Asia completing 2 years of treatment

著录项

相似文献

相关主题

期刊订阅